Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002629852 | SCV003523534 | likely benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2024-01-16 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003229937 | SCV003927772 | uncertain significance | not provided | 2023-05-22 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004676169 | SCV005177694 | uncertain significance | Inborn genetic diseases | 2024-04-23 | criteria provided, single submitter | clinical testing | The c.3122A>T (p.D1041V) alteration is located in exon 9 (coding exon 9) of the ATRX gene. This alteration results from a A to T substitution at nucleotide position 3122, causing the aspartic acid (D) at amino acid position 1041 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005050763 | SCV005678851 | uncertain significance | Acquired hemoglobin H disease; Alpha thalassemia-X-linked intellectual disability syndrome; Intellectual disability-hypotonic facies syndrome, X-linked, 1 | 2024-01-09 | criteria provided, single submitter | clinical testing |